Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of Talsaclidine in Healthy Subjects
NCT02264054Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 1999
- Primary completion
- Mar 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of talsaclidine in Alzheimer's disease (AD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: [C14]-radioactivity concentration in blood up to 96 hours, [C14]-radioactivity concentration in plasma up to 96 hours and 7 more. Started Feb 1999; status: completed.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02264054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264054.